<unk> , sold under the brand name Symbicort among others, is a fixed-dose combination medication used in the management of asthma or chronic obstructive pulmonary disease (COPD). It contains budesonide, a steroid and formoterol, a long-acting β2-agonist (LABA). The product monograph does not support its use for sudden worsening or treatment of active bronchospasm. However, a 2020 review of the literature does support such use. It is used by breathing in the medication. Common (≥1/100 to <1/10) side effects include candidiasis, headache, tremor, palpitations, throat irritation, coughing, and dysphonia. Pneumonia is a common side effect in people with COPD, and other, less common side effects have been documented. There were concerns that the LABA component increases the risk of death in children with asthma, however these concerns were removed in 2017. Therefore, this combination is only recommended in those who are not controlled on an inhaled steroid alone. There is tentative evidence that typical doses of inhaled steroids and LABAs are safe in pregnancy. Both formoterol and budesonide are excreted in breast-milk.<unk>  was approved for medical use in the United States in 2006. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2019, it was the 57th most commonly prescribed medication in the United States, with more than 12million prescriptions.
Budesonide/formoterol
Beclometasone/formoterol/glycopyrronium bromide
Mometasone/formoterol
Beclometasone/formoterol
Aclidinium bromide/formoterol
Fluticasone/salmeterol
Budesonide/glycopyrronium bromide/formoterol
Glycopyrronium bromide/formoterol